Corporate Information

20 May, 2021

Regulatory

Resolutions from Annual General Meeting in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) today on May 20, 2021 held its Annual General Meeting (“AGM”). Due to the continued spread of the coronavirus and the authorities’ regula ...

19 May, 2021

Regulatory

Abliva reports positive clinical Phase 1a/b results for KL1333 including signs of efficacy in PMD patients

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases (PMD), today announced positive ...

29 April, 2021

Regulatory

Resolutions at the Extraordinary General Meeting in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) has today held an Extraordinary General Meeting. Due to the continued spread of the coronavirus and the authorities’ regulations/advice o ...

19 April, 2021

Regulatory

Notice of Annual General Meeting of Abliva AB (publ)

The shareholders of Abliva AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting on Thursday 20 May 2021.

31 March, 2021

Regulatory

Notice of Extraordinary General Meeting of Abliva AB (publ)

The shareholders of Abliva AB (publ), 556595-6538, are hereby convened to the Extraordinary General Meeting (“EGM”) to be held on Thursday 29 April 2021.

16 March, 2021

Abliva reports completion of KL1333 Phase 1a/b study

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced the completion ...

20 January, 2021

Regulatory

Abliva

Resolutions from Annual General Meeting in Abliva AB (publ)

Abliva reports positive clinical Phase 1a/b results for KL1333 including signs of efficacy in PMD patients

Resolutions at the Extraordinary General Meeting in Abliva AB (publ)

Notice of Annual General Meeting of Abliva AB (publ)

Notice of Extraordinary General Meeting of Abliva AB (publ)

Abliva reports completion of KL1333 Phase 1a/b study

Abliva appoints Ellen Donnelly as new CEO as it enters a new stage in its development

Abliva Announces Termination of License Agreement with Fortify Therapeutics

Abliva receives positive regulatory feedback from UK MHRA on KL1333 Phase II/III study plan

Abliva initiates a drug-drug interaction study and paves the way for a KL1333 pivotal study in 2021

Magnus Persson leaves the Board of Directors of Abliva AB to focus on role as founding partner at Eir Ventures

Abliva doses the first patient in its KL1333 Phase Ia/b clinical study